Potential role of hsa-mir-8072 in prostate cancer DU 145 cells

Yıl 2019, Cilt: 50 Sayı: 4, 190 - 193, 15.12.2019

Şule Ayla Cüneyd Parlayan Nihal Karakaş Eda Açıkgöz Gülperi Öktem

https://doi.org/10.16948/zktipb.519592

Öz

Potential role of hsa-mir-8072 in prostate cancer DU 145 cells

ABSTRACT

Aim: In this study, we aimed to analyze miRNA expression
between prostate cancer cell line (DU145) and prostate normal epithelial cell
lines (RWPE) and to investigate its possible role in cancer development.

Methods: Human prostate epithelial cell line (RWPE) and
prostate cancer cell line (DU145) were acquired from ATCC. Both cell lines were
maintanied in RPMI 1640 medium.  Total
RNA were isolated and fragmented. Adapters were ligated to prepare RNA library
for whole trasncriptome experiments. Statistics and bioinformatics analysis
including mapping, clustering, sequencing were done by using Genomics Workbench
v 8. software.  

Results: As we compared the normal prostate ephitalial cells
(RWPE) and prostate cancer cells (DU 145); miRNA (hsa-mir-8072) were
significantly (p<0.05) up-regulated in DU145 cells.

Conclusion: This result suggests that the hsa-mir-8072
expression may play a role as a oncogen in prostate cancer.

Anahtar Kelimeler

cancer, miRNA, oncogene

DU 145 İnsan prostat kanseri hücrelerinde hsa-mir-8072’nin potansiyel rolü

Öz

DU 145 İnsan prostat kanseri hücrelerinde hsa-mir-8072’nin potansiyel rolü

ÖZET

Amaç: Çalışmamızda, insan prostat kanser hücre hattı (DU145)
ve prostat normal epitel hücre hatları (RWPE) arasında miRNA ifadesinin
analizini yapmak ve kanser gelişiminde olası rolünü incelemeği amaçladık.

Metod: İnsan prostat epitel hücre hattı (RWPE) ve prostat
kanseri hücre hatları (DU-145) Amerikan Tip Kültür Koleksiyonu (ATCC)’den temin
edildi. Hücre hatlarının çoğaltılmasında ve sürdürülmesinde RPMI 1640 besi
ortamı kullanıldı. Transkriptom analizi için RNA izolasyonu yapılarak,
kütüphane oluşturuldu, kütüphanenin kantitasyonunun ardından NextSeq500
(illumina) ile sekanslama yapıldı. Dizileme, haritalandırma, bağıl gen ifade
ölcümleri gibi biyoinformatik analizler Genomics Workbench v 8 yazılımı
kullanılarak GRCh38 referans sekansı ile yapıldı.

Bulgular: RWPE normal prostat epitel hücre kültürleri ile
DU145 prostat kanser hücreleri karşılaştırıldığı zaman DU-145 prostat kanser
hücre kültürlerinde, miRNA (hsa-mir-8072) ifadesinde anlamlı bir artma
(p<0,05) görüldü.

Sonuç: Bu sonuç bize hsa-mir-8072 ifadesinin prostat
kanserinde onkogenik miRNA olarak rol oynayabileceğini düşündürdü.

Anahtar Kelimeler

kanser, miRNA, onkogen

Kaynakça

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
• 2. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967-2000.
• 3. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017;317(24):2532-42.
• 4. Barron N, Keenan J, Gammell P, Martinez VG, Freeman A, Masters JR, et al. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer. Prostate. 2012;72(11):1193-9.
• 5. Lowrance WT, Scardino PT. Predictive models for newly diagnosed prostate cancer patients. Rev Urol. 2009;11(3):117-26.
• 6. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, et al. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 2012;42(6):541-7.
• 7. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-42.
• 8. Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer. Br J Surg. 2007;94(1):23-30.
• 9. Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncol. 2014;10(6):1027-48.
• 10. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3-4):369-78.
• 11. Ruvkun G. Molecular biology. Glimpses of a tiny RNA world. Science. 2001;294(5543):797-9.
• 12. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9.
• 13. Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M. The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(3):208-17.
• 14. Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, et al. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. PLoS One. 2015;10(11):e0142373.
• 15. Leung YK, Chan QK, Ng CF, Ma FM, Tse HM, To KF, et al. Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. PLoS One. 2014;9(5):e98037.
• 16. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130-5.
• 17. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68(15):6162-70.
• 18. Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128-41.
• 19. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A. miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014;15(11):1444-55.
• 20. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882-91.
• 21. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol. 2010;4(3):230-41.
• 22. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer. 2004;39(2):167-9.
• 23. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-33.
• 24. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628-32.
• 25. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537-45.
• 26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257-61.
• 27. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009;27(3):307-11.
• 28. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS. 2007;115(10):1090-106.
• 29. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer. 2010;103(8):1144-8.
• 30. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-9.
• 31. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-801.
• 32. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647-58.
• 33. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517-23.
• 34. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164(1):101-5.
• 35. Bian X, Shen Y, Zhang G, Gu C, Cai Y, Wang C, et al. Expression of dicer and its related miRNAs in the progression of prostate cancer. PLoS One. 2015;10(3):e0120159.
• 36. Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma CH. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol. 2009;55(3):563-74.
• 37. Cooper CS, Campbell C, Jhavar S. Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. Nat Clin Pract Urol. 2007;4(12):677-87.
• 38. Omelia EJ, Uchimoto ML, Williams G. Quantitative PCR analysis of blood- and saliva-specific microRNA markers following solid-phase DNA extraction. Anal Biochem. 2013;435(2):120-2.
• 39. Wang Z, Luo H, Pan X, Liao M, Hou Y. A model for data analysis of microRNA expression in forensic body fluid identification. Forensic Sci Int Genet. 2012;6(3):419-23.
• 40. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733-41.